SAGIMET BIOSCIENCES INC SERIES A (SGMT)
Health Care · Clinical-stage biopharmaceutical / metabolic and fibrotic disease therapeutics · NASDAQ
Clinical-stage biotech leveraging selective FASN inhibition to treat MASH, acne, and fibrotic diseases with a Phase 2b-validated lead candidate.
What SAGIMET BIOSCIENCES INC SERIES A does
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases. The company's lead candidate, denifanstat, is an oral selective FASN inhibitor in Phase 2b development for metabolic dysfunction-associated steatohepatitis (MASH), acne, and select cancers. A second candidate, TVB-3567, is in development for acne. The company also develops combination therapies pairing denifanstat with existing drugs to address unmet medical needs.
Themes: ["MASH (metabolic dysfunction-associated steatohepatitis) / liver disease","Fatty acid synthase inhibition","Metabolic dysfunction / steatotic liver disease","Fibrosis regression / anti-fibrotic therapy","Acne treatment","Dermatology","Cancer (select forms)"]
Fundamentals
- Price$7.35 as of 2026-07-09 close
- Market cap$450M as of 2026-07-10
- 1-year return-22.6% as of 2026-07-09 close
- Net margin-1393.8% as of 2026-07-10
- ROE-37.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta3.44 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial risk: denifanstat met Phase 2b primary endpoints in FASCINATE-2 but adverse event-driven discontinuation was 19.6% vs 5.4% placebo, creating safety tolerance risk in larger trials and commercial use","Regulatory and development uncertainty: company pursuing non-cirrhotic and cirrhotic MASH indications with no approved MASH therapeutics as benchmark; reliance on partnership with Ascletis for China development and non-dilutive funding for combination trials limits control","Financial runway and capital requirements: unprofitable clinical-stage company with negative 1393.8% net margin; successful development requires substantial additional capital for Phase 3 trials, manufacturing scale-up, and commercial launch"]
Competitors & peers
- Gilead Sciences (GILD) - MASH pipeline including resmetirom (Rezdiffra)
- Eli Lilly (LLY) - GLP-1 receptor agonists and MASH development
- Viking Therapeutics (VKING) - GLP-1/GCG receptor agonist for metabolic disease
- Novo Nordisk (NVO) - GLP-1 receptor agonists
- Madrigal Pharmaceuticals (formerly Intercept Biosciences) - obeticholic acid for MASH
- Rgenix (private) - MASH therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.